Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target at $114.15

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned an average rating of “Hold” from the twenty-two brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $113.45.

A number of equities analysts have recently issued reports on the stock. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Morgan Stanley lowered their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Tuesday, May 6th.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $95.23 on Friday. The firm has a market capitalization of $18.84 billion, a P/E ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet has a 52 week low of $89.92 and a 52 week high of $122.17. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $103.89 and its two-hundred day moving average is $105.97.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm’s revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.94 earnings per share. Research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth $25,000. Garde Capital Inc. acquired a new position in shares of Zimmer Biomet during the 1st quarter worth $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Zimmer Biomet during the 1st quarter worth $30,000. Columbia River Financial Group LLC purchased a new stake in Zimmer Biomet during the 1st quarter worth about $30,000. Finally, Menard Financial Group LLC purchased a new stake in Zimmer Biomet during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.